Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
D000818:Animals; D002478:Cells, Cultured; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000882:Haplorhini; D006454:Hemoglobins; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007928:Lethal Dose 50; D008251:Macaca; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D012075:Remission, Spontaneous; D012995:Solubility; D013997:Time Factors; D014184:Transplantation, Homologous
D006027:Glycosides; D006454:Hemoglobins; D011034:Podophyllotoxin